Stoke Therapeutics (STOK) financial statements
Stoke Therapeutics reported revenue of $184M in fiscal 2025, up 145.9% a year over 3 years.
Net income was -$7M.
Free cash flow was $45M.
The diluted share count rose 8249% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Stoke Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $12M | $9M | $37M | $184M |
| Research and development | $8M | $24M | $32M | $54M | $78M | $82M | $89M | $138M |
| Selling, general and admin | $4M | $12M | $21M | $32M | $39M | $41M | $49M | $67M |
| Operating income | -$13M | -$36M | -$53M | -$86M | -$104M | -$115M | -$101M | -$21M |
| Interest expense | — | — | — | — | — | $49,000 | $26,000 | $9,000 |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | -$13M | -$32M | -$52M | -$86M | -$101M | -$105M | -$89M | -$7M |
| EPS (diluted) | -$17.65 | -$1.80 | -$1.56 | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Diluted shares | 1M | 18M | 33M | 37M | 39M | 44M | 54M | 59M |
| Operating margin | — | — | — | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Net margin | — | — | — | — | -814.7% | -1192.5% | -243.4% | -3.7% |
Balance sheet
Fiscal years, from Stoke Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $105M | $222M | $287M | $220M | $230M | $201M | $217M | $285M |
| Receivables | — | — | — | — | — | — | $2M | $6M |
| Total current assets | $106M | $226M | $294M | $229M | $244M | $215M | $233M | $306M |
| Property, plant and equipment | $1M | $3M | $3M | $4M | $7M | $6M | $4M | $3M |
| Total assets | $108M | $229M | $298M | $239M | $256M | $228M | $272M | $418M |
| Total current liabilities | $2M | $4M | $11M | $17M | $31M | $31M | $40M | $58M |
| Total liabilities | $2M | $4M | $12M | $21M | $71M | $69M | $43M | $66M |
| Shareholders' equity | $105M | $224M | $286M | $218M | $185M | $160M | $229M | $352M |
| Net debt | -$105M | -$222M | -$287M | -$145M | -$114M | -$191M | -$128M | -$84M |
Cash flow
Fiscal years, from Stoke Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11M | -$31M | -$42M | -$67M | -$32M | -$81M | -$87M | $46M |
| Capital spending | $935,000 | $2M | $1M | $1M | $4M | $2M | $203,000 | $670,000 |
| Free cash flow | -$12M | -$33M | -$43M | -$68M | -$36M | -$83M | -$87M | $45M |
| Stock-based compensation | $240,000 | $2M | $6M | $16M | $23M | $25M | $27M | $32M |
| Free cash flow margin | — | — | — | — | -288.8% | -941.7% | -238.1% | 24.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for STOK.
Open STOK in InvestinglyQuestions
What was Stoke Therapeutics's revenue in 2025?
$184M in fiscal 2025, from its 10-K filing.
How much free cash flow does Stoke Therapeutics generate?
$45M in fiscal 2025 (operating cash flow minus capital spending).
From Stoke Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.